Table 2.
Cost inputs
| Drug cost per infusion, € | Administration cost per infusion, € | Dosing schedule | Source | |
|---|---|---|---|---|
| Drug costs | ||||
| Avelumab 800 mg (IV) | 2605.36 | 192.93 | 2 infusions per 4 weeks | Z-index, Franken et al. 2018 [28], avelumab summary of product characteristics [8] |
| BSC | 0 | 0 | NA | Assumption |
| Unit cost, € | PFS frequency | PD frequency | Source | |
|---|---|---|---|---|
| Resource costs | ||||
| Oncologist visit | 305.47 | 1 per month | 1 per month | ZIN costing manual |
| Home-care | 70.85 | 1 per month | ZIN costing manual | |
| GP home visit | 61.08 | 1 per month | ZIN costing manual | |
| Terminal care costs | 6545.71 | Upon death | NZA DBC zorgproducten | |
| Informal care costs | 17.10 | 6 h | 10 h | ZIN costing manual |
| Travel expenses | 6.91 | 1 per month | 1 per month | ZIN costing manual |
BSC best supportive care, DBC drug treatment combination, GP general practitioner, IV intravenous, NA not applicable, NZA Nederlandse zorgautoriteit, OS overall survival, PD progressive disease, PFS progression-free survival, ZIN Zorginstituut Nederland